There have been incredible responses to treatments for chronic lymphocytic leukemia (CLL), but there remains a tremendous unmet need for patients, said Brian Koffman, MDCM, DCFP, DABFM, MS Ed, medical director, CLL Society.
There have been incredible responses to treatments for chronic lymphocytic leukemia (CLL), but there remains a tremendous unmet need for patients, said Brian Koffman, MDCM, DCFP, DABFM, MS Ed, medical director, CLL Society.
Transcript
What has been the progress in treatments for chronic lymphocytic leukemia?
What I say to patients is: “There’s never a good time to have a CLL diagnosis, but there’s never been a better time.” And the best treatments today will be upstaged by better treatments tomorrow.
So, right now we’re looking at a significant percentage of CLL patients who—we’ve always had this group, but we’ve better defined them now—will never need treatment and will have the same life expectancy of an age-matched cohort. We’re also looking at data for some of the patients who get ibrutinib, a [Bruton’s tyrosine kinase] inhibitor frontline, who have the same life expectancy, again, as a matched cohort. So, these aren’t cures, but they’re incredible responses.
There’s still tremendous unmet need for CLL patients, though. Some patients can’t tolerate the treatments. Some patients progress on the treatments. And our follow-up therapies aren’t necessarily as good. Also, patients develop complications of the treatments, or of the disease itself. All CLL patients are immunocompromised, so they have a higher risk of infections, which is often a fatal event, and they often succumb to secondary malignancies—50% of CLL patients get some sort of secondary malignancy. So, we need to be looking at therapies for that group, and that’s where therapies like [chimeric antigen receptor] T and some of the combinations of novel therapies or combinations of novel therapies with chemoimmunotherapies are coming into play.
Reviving the Classics: The Role of Older Medications in Modern Dermatology
March 9th 2025Older, generic medications, including ones for cyclosporine, nicotinamide, and dapsone, can effectively treat patients with various dermatological conditions while helping to reduce insurance and cost barriers.
Read More
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Ruxolitinib Cream Shows Long-Term Safety in AD, Potential for PN Treatment
March 8th 2025Two posters presented at the 2025 American Academy of Dermatology Annual Meeting reaffirmed the impact of ruxolitinib cream (Opzelura; Incyte) in atopic dermatitis (AD), while late-breaking research highlighted its potential efficacy in prurigo nodularis (PN).
Read More
Higher UTI Risk After Spinal Fusion in Patients With Certain Comorbidities
March 5th 2025A study investigated the incidence of postoperative urinary tract infections (UTIs) in patients undergoing spinal fusion for deformities, finding that patients with more than 12 levels fused had the highest UTI rates.
Read More